SPECIAL NOTICE
Q -- Synthetic lethal screening in isogenic cell lines
- Notice Date
- 7/29/2020 8:20:34 AM
- Notice Type
- Special Notice
- NAICS
- 541714
— Research and Development in Biotechnology (except Nanobiotechnology)
- Contracting Office
- NATIONAL INSTITUTES OF HEALTH NICHD BETHESDA MD 20817 USA
- ZIP Code
- 20817
- Solicitation Number
- HHSNHorizon07292020
- Response Due
- 8/14/2020 5:00:00 AM
- Archive Date
- 08/29/2020
- Point of Contact
- MOE FILALI, Phone: 3018277737
- Description
- DESCRIPTION: The National Institutes of Health - NICHD intends to procure the services ofa contractor to provide Synthetic lethal screening in isogenic cell lines. Scientists in the SDRRM conduct laboratory research to translate genomic and genetic research into a greater understanding of human genetic disease, and to develop better methods for the detection, prevention and treatment of heritable and genetic disorders. Of particular interest is human DNA polymerase iota, which was discovered by scientists in my laboratory in 1999.� However, the cellular function of DNA polymerase iota remains unknown.� The proposed project aims to uncover pathways in which DNA polymerase participates and will therefore lead to a better understanding of DNA polymerase iota�s cellular function in human cells. The project proposes to utilize high throughput whole genome CRISPR knock-out screening assays with two isogenic (POLI +/+ and POLI -/-) human cell lines.� It is anticipated that this approach will identify genes that cause synthetic lethality in the absence of POLI.� By identifying such genes, we will be able to determine the molecular pathway(s) in which DNA polymerase iota normally operates.�� This will then allow the Lab to plan future experiments to identify the cellular function of human DNA polymerase iota. This is a unique project that entails the use of a high throughput cell-survival assays and proprietary software to analyze the data collected.� The proposed project will be completed in approximately 5 months by a team of scientists.� By comparison, if a similar study were to be performed in NIH laboratory, it would be low-throughput and would take one person 2-3 years to complete the project.� In addition, the Lab does not have access to the proprietary software needed to analyze the data generated. Thus, contracting out this project, saves time, effort and money and allow the program to move the project forward quickly. This is a unique high throughput cell-survival assay that can only be completed by scientists at Horizon Discovery.� In particular, they will carry out the specific CRISPR screening as follows: �Growth rate evaluation in two isogenic cell lines �Antibiotic sensitivity determination �Functional MOI and transduction optimization �Cell line Tier classification �CRISPR ko screening using HZD whole-genome CRISPR ko library (8 guides per gene) �Gene-gene interaction screening in two pre-evaluated isogenic cell lines (TBD) �Lentivirus manufacture and functional titration �Transduction, selection and expansion of transduced cells �Proliferation-based end-point screening �Screen maintenance at 300X coverage for 12 population doublings (or 35 days) �End point cell pellet collections, DNA purification, amplification and NGS prep �NGS, Screen QC and Hit calling (statistical analysis & data visualization; LFC, FDR, RRA, Bagel) This proposed procurement is for products and services for which the government intends to solicit and negotiate on a sole source basis to Horizon Discovery located in Cambridge, UK. �In order to comply with the requirements in this Solicitation, the responses should be based on our interpretation of the general requirements provided below. This solicitation is not a request for competitive quotes. However, all quotes received within the time and date of publication of this "" Notice"" will be considered by the Government, evaluated and an ensuing award will be made thereafter to the lowest technically-acceptable price. HOW TO RESPOND: In order to compete for this project, interested parties must be registered in the Central Contracting Registration and submit a price quotation by 9 am, ET, August 14th �, 2020. Offerors should submit one copy of the quote to MOE FILALI via email. Electronic transmissions to Moe.Filali@nih.gov are preferable but must be timely. It is the responsibility of the Offeror to ensure the proposal is received by the date and time shown above.� All questions should be directed earlier. The following Federal Acquisition Regulations clauses are incorporated by reference: FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Mar 2005), 52.212-4 (Sept 2005), 52.212-5, Contract Terms and Conditions Required to Implement Statutes of Executive Orders-Commercial Items (Aug 2006). (6)(i) 52.222-26, Equal Opportunity (Apr 2002) (E.O. 11246). (18) 52.222-35, Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Dec 2001) (38 U.S.C. 4212). (19) 52.222-36, Affirmative Action for Workers with Disabilities (Jun 1998) (29 U.S.C. 793). (20) 52.222-37, Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Dec 2001) (38 U.S.C. 4212). (31) 52.232-33, Payment by Electronic Funds Transfer-Central Contractor Registration (Oct 2003) (31 U.S.C. 3332). Primary Point of Contact: MOE FILALI Contracting Office Address: � NIH/NICHD Office of Acquisitions 6710B Rockledge Drive, Room 1145D Bethesda, MD 20817 (w) 301.827 7737 Moe.filali@nih.gov �
- Web Link
-
SAM.gov Permalink
(https://beta.sam.gov/opp/ad97f933d7ed4746aa305a7f6b7452a6/view)
- Place of Performance
- Address: Bethesda, MD 20892, USA
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN05737276-F 20200731/200729230141 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |